CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
Item 9.01. Financial Statements and Exhibits.
| 99.1 | Press release of Corvus Pharmaceuticals, Inc., dated May 9, 2019. |
Corvus Pharmaceuticals, Inc. Exhibit
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results Announces Initiation of Enrollment in Phase 1/1b Trial of ITK inhibitor CPI-818 Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME,…
To view the full exhibit click here
About CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS)
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.